Loading organizations...
Capra Biosciences is a Manassas, Virginia-based biotechnology company that develops biofilm-based continuous flow bioreactors to produce sustainable chemicals from industrial waste, effectively replacing traditional petrochemicals. The company's proprietary hardware platform utilizes 100 times less water than conventional manufacturing methods and costs approximately $1,000 per bioreactor unit to deploy. By converting agricultural side streams like thin stillage and glycerol into high-value compounds such as bio-retinol for cosmetics and industrial lubricants, the business achieves gross margins of up to 90 percent. To scale its operations and expand its laboratory spaces, the enterprise secured $1.8 million in pre-seed funding alongside additional pilot-scale production grants from BioMADE. This financial backing was provided by a syndicate of recognizable venture capital investors including SOSV, Prithvi Ventures, E14 Fund, and GS Futures. Capra Biosciences was founded in 2020 by Elizabeth Onderko and Andrew Magyar.
Capra Biosciences has raised $5.0M across 2 funding rounds.
Capra Biosciences has raised $5.0M in total across 2 funding rounds.
Capra Biosciences has raised $5.0M in total across 2 funding rounds.
Capra Biosciences's investors include Alumni Ventures, Cyphr VC, Underscore VC, Max Blumenthal, BITKRAFT Ventures, Mayfield, Pioneer Fund, SOSV, Wes Osbourn, Asymmetry Ventures, Decarbonization Consortium, E14 Fund.
Capra Biosciences has raised $5.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $3M Seed | — | Alumni Ventures, Cyphr VC, Underscore VC, MAX Blumenthal | Announced |
| Jun 1, 2022 | $2M Seed | — | BITKRAFT Ventures, Mayfield, Pioneer Fund, SOSV, WES Osbourn, Asymmetry Ventures, Decarbonization Consortium, E14 Fund, GS Futures, Prithvi Ventures, Savantus Ventures | Announced |
Capra Biosciences is a biotech startup founded in 2020 that develops sustainable, bio-based chemicals using a proprietary biofilm bioreactor technology to replace petrochemicals.[1][2][5] The company produces high-performance renewable chemicals, starting with bio-Retinol for the cosmetics market—targeting anti-aging products—and planning expansion into lubricants for the $150 billion motor oil sector.[1][2][4] It serves industries like cosmetics and automotive by converting waste carbon sources, such as food waste, into valuable molecules, solving the problem of costly, fossil fuel-dependent production through a process that cuts water use by up to 100X, minimizes infrastructure, and reduces CAPEX/OPEX by up to 90%.[1][3] Backed by investors like Closed Loop Partners and emerging from SOSV's IndieBio accelerator, Capra has raised an oversubscribed pre-seed round, expanded lab space, hired a small team (2-10 employees), and aims for a pilot plant to scale retinol production.[1][2][3]
Capra Biosciences was founded in 2020 by Elizabeth Onderko, who invented the core biofilm bioreactor technology during her National Research Council Postdoctoral Fellowship at the U.S. Naval Research Laboratory (NRL).[2][5] Collaborators included her advisor Dr. Sarah Glaven, Dr. Matthew Yates, and Dr. Andrew Magyar, building on insights that 99% of bacteria naturally exist in biofilms for efficient production—flipping the script on traditional fermentation where biofilms are a hindrance.[1][2] The idea emerged from NRL research on microbial biofilms for sustainable chemical synthesis. Early traction came from graduating the competitive IndieBio program by SOSV, starting on a shared bench at the Prince William Science Accelerator, expanding to dedicated labs in 2022, securing an oversubscribed pre-seed round, and hiring full-time staff while interning students via Virginia Bio's STEM2VA program.[2]
Capra stands out in synthetic biology through its patented continuous-flow biofilm bioreactor, which packs microbes densely for teamwork-like efficiency, enabling cheaper, greener production of petrochemical replacements.[1][2][3][5]
Capra rides the synthetic biology wave for circular economy solutions, transforming waste carbon into high-value chemicals amid rising demands for supply chain resilience, decarbonization, and reduced petrochemical dependence.[3][4] Timing aligns with global pushes for sustainable manufacturing—post-2020 supply disruptions highlighted vulnerabilities in fossil fuel chains, while food waste (billions of tons annually) offers cheap feedstocks versus volatile sugar prices.[3] Market forces like cosmetics' lucrative retinol demand ($1B+ anti-aging segment) and motor oil's $150B scale favor Capra's cost-competitive biology, bolstered by U.S. biohub growth in Virginia.[1][2] It influences the ecosystem by proving NRL tech transfer works, inspiring distributed biomanufacturing that cuts transport emissions and supports national defense strategies via resilient, local production.[2][3]
Capra is poised to scale its pilot plant for bio-Retinol commercialization within the next year, unlocking revenue from cosmetics before pivoting to lubricant base oils and broader petrochemical replacements.[2] Trends like advancing synbio tools, stricter ESG regulations, and waste valorization policies will accelerate adoption, potentially positioning Capra as a leader in affordable bio-chemicals if it nails unit economics.[1][3] Its influence may grow through partnerships, expanding the biofilm model to new molecules and feedstocks, ultimately reshaping extractive industries with resilient, waste-fueled production—echoing its origins in flipping fermentation's biggest "problem" into biotech's next efficiency edge.[1][2][5]
